India, Oct. 28 -- The shares of this global pharmaceutical, health and wellness company operating across three key businesses, including Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG), and Piramal Consumer Healthcare (PCH) are in the spotlight after it rose by 15 per cent in today's session following its Q2 results, supported by CDMO business growth.

With a market capitalisation of Rs. 30,115 cr, the shares of Piramal Pharma Ltd were trading at Rs. 226.50 per share, making a high of Rs. 228 in today's market session, increasing 15% from its previous close of Rs. 198.45 per share.

Financial Performance: Revenue Rises 28% YoY and 15% QoQ Piramal Pharma reported consolidated revenue from oper...